Please enable JavaScript in your browser. 

Important Announcement

X

DrugPortal is moving to PubChem in December 2022.
Please see the NLM Technical Bulletin article for more information.

Skip to main content
Drug Information Portal National Library of Medicine
Home
 
       Home    Substance
     
Result
PropertyValue
Drug Name: Pacritinib [USAN:INN] View Structure
Description: For treating lymphoma and myelofibrosis.

NCI: An orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity. Pacritinib competes with JAK2 for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, and so caspase-dependent apoptosis. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders; the JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity. (NCI Thesaurus) 
Category:



 
 
Site Map, Contact Us, Copyright, Privacy, Accessibility
U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894
National Institutes of Health, Health & Human Services
Freedom of Information Act
HHS Vulnerability Disclosure
Drug Information Portal Mobile Site
Last updated: Oct 2022
USA.gov